Drug products: Ketotifen STADA, Zaditen, Zaditen Defiante, Zaditen Novartis, Zaditen®, Zalerg, Zasten
ATC code: R06AX17, S01GX08
Substances: ketotifen, ketotifen fumarate
There are no published controlled studies on differences between the sexes regarding efficacy, safety and pharmacokinetics of ketotifen.
The prevalence of self-reported allergic rhinoconjunctivitis symptoms was in a Swedish population study (n=10,670) similar in men and women . Ketotifen is topically used in allergic conjunctivitis. Systemic exposure of ketotifen in topical administration can be expected to be very low or absent based on a study where plasma levels were not detectable when given the ophtalmic route .
No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of ketotifen have been found.
No studies with a clinically relevant sex analysis regarding effects of ketotifen have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of ketotifen have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2022-08-04
Reviewed by: Diana Rydberg, Carl-Olav Stiller, Pauline Raaschou
Approved by: Karin Schenck-Gustafsson